The present data indicated that JDX or serum containing JDX management contributed to the tumor growth inhibition effect and reconstitution of tumor inflammatory microenvironment by enhancing the secretion and expression of IL-2, IL-10, IL-12, IL-17, TNF-α, and IFN-γ and inhibiting the levels of TGF-β, VEGF, and MMP-9 in mice bearing lymphoma tumor after APBSCT. Here, IL17A is linked to neoplasm.